Redx Pharma is the UK’s fastest growing life sciences company. It is focused on early stage drug development operating in three clinical areas – cancer, infectious diseases and metabolic illnesses. Its scientists research new drug candidates in laboratories, and enter into licensing agreements with big pharma companies for the most promising compounds. Redx Pharma has become a global player in just four years.
We have worked with Redx Pharma since its formation. Our job is to deliver proactive, comprehensive media relations support across the business and pharma press, and create social media communications campaigns. Our role is to reflect and amplify Redx’s credentials as the UK’s most exciting life sciences business. We assist Redx Pharma in its collaboration with key partners in the public and private sector, working closely with big pharma customers, NHS Trusts, life sciences lobby groups and economic development organisations. In each case we provide board-level advice on win-win profile.
Redx is a high profile business for all the right reasons. It has appeared on the BBC Today programme, Sky News, BBC Breakfast, BBC Five Live, in The Financial Times as well as key global industry titles such as Scrip and BioCentury. Our activity beyond media relations includes social media, podcasts and collaboration on the production and delivery of major events. We worked with Redx to facilitate the international BioInfect conference on the global threat of antibiotic resistance (AMR). Speakers included UK Chief Medical Officer Dame Sally Davies, Redx Pharma’s CEO Dr Neil Murray, plus a global panel of leading industry experts. We secured the active support and engagement of Scrip, a leading title for the life science industry in Europe, which attended and produced a microsite to capture the learnings from the event.